New clinical results with sGC stimulators
نویسندگان
چکیده
منابع مشابه
New clinical results with sGC stimulators
Background Stimulators of the nitric oxide (NO) receptor soluble guanylate cyclase (sGC) are a new class of substances which enhance the biosynthesis of cyclic guanosin monophosphate (cGMP) independently from the presence of nitric oxide (NO). In pulmonary smooth muscle cells, increased intracellular cGMP concentrations lead to vasodilatation, making sGC-stimulators potentially useful for the t...
متن کاملNO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272
BACKGROUND The most important receptor for nitric oxide is the soluble guanylate cyclase (sGC), a heme containing heterodimer. Recently, a pyrazolopyridine derivative BAY 41-2272, structurally related to YC-1, was identified stimulating soluble guanylate cyclase in an NO-independent manner, which results in vasodilatation and antiplatelet activity. The study described here addresses the identif...
متن کاملsGC activators and stimulators attenuate ischemia/reperfusion injury of the lung
Background Protective effects of NO, a physiological activator of soluble guanylyl cyclase (sGC), have been reported in ischemia/reperfusion syndrome (I/R) of the lung. However, its protective effects can be overwhelmed by its deleterious effects due to oxidative products formation. Therefore, we studied the effects of direct sGC stimulator (BAY 41-2272) and sGC activator (BAY 58-2667) on I/R i...
متن کاملEffects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis
Urinary colics from calculosis are frequent and intense forms of pain whose current pharmacological treatment remains unsatisfactory. New and more effective drugs are needed to control symptoms and improve stone expulsion. Recent evidence suggested that the Nitric Oxide (NO) / cyclic guanosine monophosphate (cGMP)/phosphodiesterase type 5 (PDE5) system may contribute to ureteral motility influe...
متن کاملNew vitamin B12 derivatives activates sGC
Background Protoporphyrin IX (PPIX) was shown to strongly activate in vitro the soluble guanylate cyclase enzyme (sGC), which makes it an interesting drug candidate for treatment of hypertension [1,2]. In order to overcome the problem of PPIX poor bioavailability (especially in the case of oral administration), we decided to exploit the specific uptake pathway of vitamin B12, which was frequent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Pharmacology
سال: 2011
ISSN: 1471-2210
DOI: 10.1186/1471-2210-11-s1-o2